glp-1 litigation Judicial Panel Authorizes New Vision Loss Zepbound Lawsuit [2026] | Gastrointestinal
Description
The reported acute effects of cannabis on bronchodilation are attributed to the activity of 9 -THC on the CB1 receptors of the axon terminals of postganglionic vagal nerves in the airway [64]
![glp-1 litigation Judicial Panel Authorizes New Vision Loss Zepbound Lawsuit [2026] | Gastrointestinal](https://www.torhoermanlaw.com/wp-content/uploads/2026/02/Zepbound-Lawsuit-Other-Drugs-and-Manufacturers-Named-in-the-GLP-1-Lawsuits-torhoerman-law.jpg)
On the same measure, cumulative revenues across the major pharmaceutical companies alone are projected to reach close to $165 billion by 2030 (Figure 1)
![glp-1 litigation Judicial Panel Authorizes New Vision Loss Zepbound Lawsuit [2026] | Gastrointestinal](https://www.llamalab.ai/optimized/blogs/glp-1-litigation-2026.webp)
95% confidence interval [CI], 3.69 to 2.30) [32]
![glp-1 litigation Judicial Panel Authorizes New Vision Loss Zepbound Lawsuit [2026] | Gastrointestinal](https://www.draftncraft.com/wp-content/uploads/2026/02/Screenshot-2026-02-25-at-11.37.33-AM.png)
Ongoing research and development efforts, including novel formulations, dual- and triple-agonist therapies, and extended-release oral agents, hold promise for enhancing accessibility, tolerability, and sustained benefits
![glp-1 litigation Judicial Panel Authorizes New Vision Loss Zepbound Lawsuit [2026] | Gastrointestinal](https://www.drugwatch.com/wp-content/uploads/Do-I-Qualify-Ozempic.png)
Tirzepatide compared to semaglutide already showed that dual-receptor agonism outperforms single-receptor activation
![glp-1 litigation Judicial Panel Authorizes New Vision Loss Zepbound Lawsuit [2026] | Gastrointestinal](https://www.foley.com/wp-content/uploads/2025/02/glp1injection.jpg)